NETRF Works to Take PRRT to Next Level
July 25, 2018|
The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor Radionuclide Therapy (PRRT).
Improving efficacy and safety
Three NETRF-funded studies are looking at how existing approaches to PRRT can be improved to:
- Expand the number of patients able to benefit from PRRT
- Increase its precision to target even the smallest signs of cancer
- Reduce the toxicity of current treatments
In this video, you will meet the researchers who are exploring methods that may improve the benefits of PRRT for more people. Learn what they hope to discover.
PRRT: A promising advancement
PRRT is a promising treatment of neuroendocrine tumors (NETs). Research shows PRRT can help to:
- Increase survival
- Improve quality of life
- Relieve symptoms
- Decrease tumor size
PRRT is generally well tolerated. Common side-effects are nausea, vomiting, and abdominal pain. Other less common side-effects are bone, liver, and kidney toxicity, and mild hair loss. But not everyone benefits from PRRT.
Attracting the best and brightest
As the major private funder of NET research, NETRF is able to quickly pursue a promising advance in medicine like PRRT to recruit the most talented experts in the world.
“NETRF harnessed the world’s leading experts in PRRT to help us advance this therapeutic option to increase the benefits and reduce the risks,” said Elyse Gellerman, NETRF Chief Executive Officer.
All research grants are made possible by generous gifts to the NET Research Foundation from patients, families, and friends of those who want to improve options for those affected by NETs.
More from NETRF.